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SUMMARY
BACKGROUND AND OBJECTIVES: Chronic obs-
tructive pulmonary disease (COPD) is defined as 
a syndrome characterized by usually progressive 
chronic airflow limitation which is associated to a 
bronchial hyperresponsiveness and is partially re-
versible. Noninvasive mechanical ventilation is an 
alternative treatment for patients with COPD exa-
cerbations. The objective of the literature reviews 
was to verify noninvasive mechanical ventilation 
benefits and complications in acute exacerbations 
of chronic obstructive pulmonary disease in pa-
tients. 
CONTENTS: This national and international’s 
scientific literature review was developed accor-
ding to criteria established for documentary rese-
arch in the MedLine, LILACS, SciElo, PubMed and 
Cochrane, databases using the key words: chronic 
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obstructive pulmonary disease and noninvasive 
mechanical ventilation. Inclusion criteria were arti-
cles published from 1995 to 2007; in English, Spa-
nish and Portuguese; studies in the human model 
and with no gender restriction.
CONCLUSIONS: Noninvasive mechanical venti-
lation can reduce partial pressure of carbon dio-
xide, improve gas exchange, alleviate symptoms 
as dyspnea caused by fatigue of the respiratory 
muscles, reduce duration of hospitalization, de-
crease need for invasive mechanical ventilation, 
reduce number of complications and also lessen 
hospital mortality. The main complications found 
were: facial skin erythema, claustrophobia, nasal 
congestion, face pain, eye irritation, aspiration 
pneumonia, hypotension, pneumothorax, aeropha-
gia, hypercapnia, gastric insufflation, vomit, bron-
choaspiration, morning headaches, face injuries, 
air embolism and, last but not least, discomfort 
of the patient. Noninvasive mechanical ventilation 
can be more effective in patients with moderate-
severe exacerbations of COPD and these compli-
cations can be minimized by an adequate interface 
also by the contribution of the physiotherapist ex-
perience.
Key Words: Chronic obstructive pulmonary disea-
se, Noninvasive mechanical ventilation.
RESUMO
JUSTIFICATIVA E OBJETIVOS: A doença pulmo-
nar obstrutiva crônica (DPOC) é definida como uma 
síndrome caracterizada por obstrução crônica ao 
fluxo aéreo, geralmente progressiva, podendo ser 
acompanhada por hiper-responsividade brônquica 
e ser parcialmente reversível. A ventilação mecâ-
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nica não-invasiva é uma alternativa de tratamen-
to para pacientes com exacerbação da DPOC. O 
objetivo deste estudo foi verificar os benefícios 
e as complicações da ventilação mecânica não-
invasiva em pacientes com exacerbação aguda da 
doença pulmonar obstrutiva crônica.
CONTEÚDO: Realizou-se revisão de literatura 
científica nacional e internacional conforme os 
critérios estabelecidos para a pesquisa documen-
tal nas bases de dados MedLine, LILACS, SciE-
lo, PubMed, Cochrane, com os unitermos: doença 
pulmonar obstrutiva crônica, ventilação mecânica 
não-invasiva. Os critérios de inclusão foram arti-
gos publicados no período de 1995-2007; nas lin-
guagens inglesa, espanhola e portuguesa; estudos 
em modelo humano e sem restrição de sexo.
CONCLUSÕES: A ventilação mecânica não-inva-
siva pode diminuir a pressão parcial de dióxido de 
carbono, melhorar a troca gasosa, aliviar sintomas 
como dispnéia ocasionada pela fadiga da muscu-
latura respiratória, reduzir as internações hospita-
lares, a necessidade de intubação, o número de 
complicações, o tempo de internação e a morta-
lidade hospitalar. As principais complicações en-
contradas foram: eritema facial, claustrofobia, 
congestão nasal, dor facial, irritação nos olhos, 
pneumonia aspirativa, hipotensão, pneumotórax, 
aerofagia, hipercapnia, distensão abdominal, vô-
mitos, broncoaspiração, dor de cabeça matinal, 
lesões compressivas de face, embolia gasosa e 
não adaptação do paciente. A ventilação mecânica 
não-invasiva pode ser mais efetiva em pacientes 
com moderada a grave exacerbação da DPOC e 
as complicações podem ser diminuídas pela utili-
zação de adequada interface e experiência do fi-
sioterapeuta.
Unitermos: Doença pulmonar obstrutiva crônica, 
Ventilação mecânica não-invasiva.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is 
defined as a syndrome characterized by chronic 
obstruction to airways flow resulting from chronic 
bronchitis or emphysema. Obstruction of the ai-
rways flow usually is progressive and may be ac-
companied by bronchic hyperresponsiveness and 
be partially reversible1-3. 
In Brazil, there has been an increase in the num-
ber of deaths in both genders by COPD in the last 
20 years. In the decade of the eighties, mortali-
ty rate was 7.88/100,000 inhabitants increasing 
to 19.04/100,000 in the nineties, with a growth of 
340% although, in the last years COPD has been 
ranked between fourth and seventh among the 
main causes of death in Brazil4.
Patients with COPD are most often smokers with 
a history of at least one pack per day for at least 
twenty years and it is rarely found in non-smokers. 
Onset is typically in the fifth decade and often at-
tention is called to a productive cough or acute 
respiratory disease. Although there may be whee-
zing, it is not an indicator of severity of the disease. 
Disorders of gas exchange and dyspnea become 
progressive and, erythrocytes and cyanosis may 
occur with hypoxemia. Development of morning 
headaches may signal onset of significant reten-
tion of carbon dioxide (CO2.). In the advanced di-
sease, blood anomalies are severe, cor pulmonale 
may manifest through peripheral edema and water 
retention. Anxiety, depression and sleep disorders 
are frequent1,5,6. Main symptoms are effort dysp-
nea, wheezing and, usually productive cough7. 
Clinical diagnosis of CPOD should be considered 
in patients with dyspnea, chronic cough or pulmo-
nary hypersecretion, and/or a history of exposure 
to risk factors for the disease, and may be confir-
med by spirometry. Presence, post-bronchodilator 
forced expiratory volume in 1 sec (FEV1) / forced 
vital capacity (FVC) < 0.70 and FEV1 < 80% of the 
predicted, confirms presence of an airflow obs-
truction that is not totally reversible1,2 .
Symptoms found in CPOD are nonspecific findings 
and may lead to diagnostic confusion. There are 
various respiratory diseases that serve as differen-
tial diagnosis. They are: bronchial asthma, brochio-
litis, bronchioectasia, tuberculosis and congestive 
heart failure4.
The patient with CPOD has chronic and daily symp-
toms, even during the stable period. Exacerbation 
crisis is defined by the presence of three signs or 
symptoms: increase of dyspnea; greater volume of 
sputum and purulent sputum. A mild crisis means 
presence of only one sign or symptom, moderate 
crisis when there are two of these manifestations 
and severe crisis when the three manifestations 
are associated. Other clinical manifestations such 
as cough, wheezing and fever may be present, 
but do not define or classify severity of the crisis. 
More recently, exacerbation crises, were also clas-
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sified according to presence of risk factors and of 
chronic suppuration8. Exacerbations represent an 
enlargement of the inflammatory response in the 
airways of patients with CPOD and may be iden-
tified by bacterial or viral infection or by environ-
mental pollutants. During exacerbation, there is an 
increased hyperinssuflation and air retention with 
decrease of the expiratory flow, promoting incre-
ase of dyspena. There is also a worsening of the 
abnormality of the relation ventilation/perfusion 
(V/Q) bringing about severe hypoxemia2. The prin-
cipal cause is infectious. Mucus is a material rich 
in carbohydrates and bacteria with polysacchari-
des receptors may avidly adhere to mucus. This is 
the case of Haemophilus influenzae, Streptococ-
cus pneumoniae, Moraxella catarrhalis and Pseu-
domonas aeruginosa. These bacteria may colonize 
the patient with CPOD in the stable period. After 
colonization, the epithelial barrier may be broken 
as a result of release of bacterial products able to 
paralyze the cilliary movements and break the in-
tercellular junctions of the epithelium; however in-
fection is superficial and restricted to the bronchial 
mucosa. Bacterial etiology corresponds to 50% of 
cases, and in the remainder are viruses, irritant and 
allergic7-9. 
Among the extrapulmonary factors of this decom-
pensation of non-infectious causes of CPOD, it 
should be noted that most patients are elderly, 
smokers and hypoxemic with a greater probability 
of presenting with coronary failure, heart dysrhyth-
mias and heart failure in addition to other factors 
such as the use of beta-blockers, opiods and other 
drugs. About 1/3 of the causes of severe exacer-
bations are not identified5,7,8. González et al.10 sho-
wed that presence of cor pumonale, prolonged 
oxygentherapy, hypercapnia and the increase of 
the inspiratory work raise the risk of hospital ad-
mission due to exacerbation.
Yasuda et al.11 disclosed that in stable conditions 
and exacerbations, concentrations of carboxihe-
moglobin in stage III patients is higher than in sta-
ge II patients while concentrations of carboxihe-
moglobin of stage IV patients is higher than in sta-
ge III patients and, in patients with exacerbation 
of CPOD, the carboxihemoglobin concentrations 
inversely correlate with FEV1 and with partial oxy-
gen pressure(PO2).
However Franciosi et al.12 reported in a review of 
literature that arterial carbon dioxide and the respi-
ratory rate of patients with acutely ill CPOD varied 
according to the severity of exacerbation.
According to Hill et al.13 patients with protein alfa-1 
antitrypsin deficiency present exacerbations with 
high concentrations and consistency of secretions 
with a significant number of neutrophils that are 
probably a result of the high concentration of IL-8 
and LTB4. They also reported that elastase activity 
was present in most of the samples analyzed and 
that enzyme activity was probably due to severe 
factors including neutrophil recruitment. 
Standard treatment of acute exacerbation of CPOD 
consists of oxygen therapy, glucocorticoids, nebu-
lization with bronchodilators and antibiotic thera-
py1,4,8,14,15.
After comparing NIMV to IMV, studies have shown 
that the early indication of NIMV reduces need for 
tracheal intubation, time of ICU stay and occur-
rence of ventilator associated pneumonia VAP and 
mortality of patients with respiratory failure due to 
CPOD exacerbation. These studies further point to 
lesser need of intubation, lesser time of hospital 
stay, decrease in the number of complications, de-
crease of PaCO2, relief of symptoms such as dysp-
nea due to respiratory muscle fatigue15-25.
As such, noninvasive mechanical ventilation (NIMV) 
is a therapeutic alternative for patients with acute 
CPOD8. 
NIMV should be used for patients able to maintain 
upper airways permeability, as well as integrity of 
the swallow and the capacity to mobilize secre-
tions. Severe hemodynamic instability, characte-
rized by use of vasopressor amines and complex 
dysrhythmias are considered contraindications for 
use of NIMV. NIMV should not be used in patients 
with abdominal distension or vomiting because of 
risk of aspiration. Immediate esophageal surgery 
postoperative, facial trauma, acute injury and/or 
bleeding of the airways are also considered limita-
tions for use of NIVM26. 
The main objective of this study was to describe 
benefits and complications of noninvasive mecha-
nical ventilation in patients with acute exacerba-
tion of chronic obstructive pulmonary disease. 
NIMV BENEFITS AND COMPLICATIONS IN ACU-
TE EXACERBATION OF CPOD
Efficacy of NIMV in the treatment of acute exacer-
bation of CPOD was investigated by Brochard et 
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al.16 in a randomized multicentric study carried out 
in 85 patients with exacerbated CPOD, comparing 
standard treatment (oxygen therapy and drugs) 
with NIMV. During hospital admission procedures, 
both groups disclosed similar characteristics. Use 
of NIMV significantly reduced need for trache-
al intubation: 11 of the 43 patients (26%) of the 
NIMV group compared to 31 of 42 patients (74%) 
of the control group whose statistical significan-
ce was p< 0.001. Complications were significantly 
lower statistically in the NIMV (16% versus 48%, 
p = 0.001), as well as a statistically significant re-
duction in mean hospital stay for patients of the 
NIMV group (23 ± 17 days versus 35 ± 33 days, p = 
0.005). Hospital mortality rate was significantly lo-
wer in patients of the NIMV group (9% of the NIMV 
group died in comparison of 29% of the control 
group p = 0.02).
Celikel et al.15, in a randomized study compared 
use of NIMV with a control group. This study was 
carried out in 30 patients divided into 2 groups 
(NIMV and of standard treatment groups). In the 
standard treatment group only respiratory rate (RR). 
Showed a significant improvement However, in the 
NNIMV group PCO2, pH and RR improved signifi-
cantly when compared with the standard treatment 
group. Six hours after randomization, pH and RR of 
patients submitted to NIMV were significantly bet-
ter than in the standard treatment group. Hospital 
stay was shorter for the NNIMV group (11.7 ± 3.5 
days versus 14.6 ± 4.7 days, p < 0.05). Only one 
of the NIMV group was intubated. Six of the stan-
dard treatment group presented with worsening 
of the clinical condition and received NIMV, which 
was successful in four patients while the other two 
were intubated.
Brochard et al.18 reported that NIMV brings about 
quicker resolution of the physiological disorder, re-
duces need for intubation, improves survival and 
reduces infectious complications. However Ma-
tuska et al.23, reported that there was only reduc-
tion of tracheal intubation in the group using NIMV 
and there was no difference in mortality between 
NIMV and standard treatment groups. Carratu et 
al.24 stated that NIMV reduces the need for intu-
bation in 80% of patients with moderate to severe 
hypercapnic CPOD respiratory failure. 
In patients with exacerbated CPOD use of CPAP 
with PEEP of 10-12 cmH2O, reduced respiratory 
work and dyspnea27-29.
Studies by Neme et al.25 corroborated that use of 
CPAP with 3 cmH2O combined with ventilatory su-
pport pressure improved the respiratory pattern, 
increased alveolar ventilation and reduced the res-
piratory work. For Cavalheiro30 support pressure 
must be adjusted at levels that determine a tidal 
volume of 7 mL/kg.
Yosefy et al.19 proved that use of BiPAP was effec-
tive and well tolerated by patients with respiratory 
disorder reducing tracheal intubation. However, 
studies carried out by Lien et al.17 corroborate 
that early use of BiPAP in severe exacerbations of 
CPOD decreases activity of the accessory muscles 
and improves respiratory drive, reduces respira-
tory rate, improves blood gas and thoracoabdo-
mial asynchrony.
NIMV may have some adverse effects and compli-
cations, such as discomfort, facial edema, claus-
trophobia, nasal congestion, facial pain, eye irri-
tation, aspiration pneumonia, hypotension, and 
pneumothorax. Problems such as aerophagia, 
hypecapnia, abdominal distension, vomit, bron-
choaspiration, morning headaches, face compres-
sion injuries; gas embolism and lack of adjustment 
of patients are inherent to the method and may 
restrict use1,29-35.
Raghavan et al.35 showed that patients with seve-
re CPOD treated with anticoagulants are at higher 
potential risk of pulmonary barotraumas and he-
morrhage during treatment with NIMV. The authors 
reported a clinical case of a patient who developed 
hemopneumothorax as a NIMV complication.
Wood et al.36 reported that prolonged use of NIMV 
causes accretion of thick secretions.
Keenan et al.37 did not find important benefits that 
justified routine use of NIMV for mild exacerbation 
of CPOD.
Keenan et al.21 showed that such benefits were 
not demonstrated in patients with milder CPOD 
exacerbations, stressing the concept that NIMV is 
indicated for patients with more severe exacerba-
tions accompanied by hypercapnia and respiratory 
acidosis. Hess38, showed that NIMV is beneficial 
for reducing need of intubation and mortality in pa-
tients with CPOD exacerbation. 
In tables 1 and 2 some of the complications and 
benefits of NIMV in acute exacerbation of CPOD 
are described. 
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CONCLUSION
Studies analyzed after this review disclosed that 
NIMV seems to be more effective in moderate to 
severe exacerbation of CPOD. Main benefits were 
better pulmonary gas exchange, reduction of dysp-
nea, less respiratory muscular work, less intuba-
tion and invasive ventilatory support and decrease 
of mortality. The main complications found were 
facial erythema, claustrophobia, nasal congestion, 
facial pain, eye irritation, aspiration pneumonia, 
hypotension, pneumothorax, aerophagia, hiper-
capnia, abdominal distension, vomit, bronchoas-
piration, morning headaches, face compression 
injuries, gas embolism and lack of adaptation of 
patients. However these complications may be re-
duced with the use of adequate interface and with 
the experience of the physiotherapist.
Table 1 – Summary of Complications of NIMV in Acute Exacerbation of CPOD
Authors Year N. of Patients Types of Study Complications
Jasmer et al.33 1997 - Review of literature Facial ulceration and gastric distention
Criner et al.31 1999 40 Clinical case Skin irritation, aerophagia and discomfort with the 
mask
Wood et al.36 2000 1 Case report Accrual of thick secretions in prolonged use.
Mehta e Hill28 2001 - Review of literature Discomfort, facial erythema, claustrophobia, nasal ul-
ceration, nasal congestion, pain, dry mouth, eye irri-
tation, gastric insuffl ation, brochoaspiration, hypoten-
sion, pneumothorax. 
Hill32 2004 - Review of literature Nasal congestion, dry mouth, gastric insuffl ation irri-
tation to the conjunctive, sleep disorders, dyspnea, 
fatigue, morning headaches 
Raghavan et al.35 2004 1 Case report Pneumothorax, increase of respiratory work, gastric 
distention, embolysm, barotrauma.
Table 2 – Summary of the Benefits Obtained by NIMV in Acute Exacerbation of CPOD 
Authors Year N. of Patients Type of Study Complications 
Brochard et al.16 1995 85 Randomized clinical trial Reduction of tracheal intubation, decrease of compli-
cations, decrease of hospital stay
Lien et al.17 1996 10 Clinical trial Decrease of accessory muscle activity and better 
respiratory drive, reduction of respiratory rate, impro-
vement of blood gas and of thoraco-abdominal asyn-
chrony 
Celikel et al.15 1998 30 Randomized clinical trial Improvement of PO2, of PCO2, of pH and RR, decrea-
sed hospital stay, decrease of tracheal intubation.
Brochard et al.18 2002
-
Literature review 
Faster resolution of physiological disorder, lesser need 
for intubation, increases survival and reduces infec-
tious complications.
Yosefy et al.19 2003 30 Clinical trial Decreases need for tracheal intubation..
Lightowler et al.20
2003 -
Systematic review Decreases need for tracheal intubation, and reduces 
hospital mortality.
Keenan et al.21
2003 -
Systematic review Decreases need for tracheal intubation and reduces 
mortality and hospital stay.
Ram et al.22
2004 -
Systematic review Decreases need for tracheal intubation and reduces 
hospital mortality.
Carratu et al.23 2005 122 Clinical trial Decreases need for tracheal intubation by 80%
Matuska et al.24
2006 30
Randomized clinical trial Reduces tracheal intubation, no difference related to 
mortality.
Neme et al.25
2007 18
Clinical trial Improves respiratory pattern, increases alveolar venti-
lation and reduces respiratory work.
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